Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1331-1337

  Kees, Martin Georg ^a,b   André, Schaeftlein ^b   Haeberle, Helene Anna ^c   Kees, Frieder ^d   Kloft, Charlotte ^b   Heininger, Alexandra ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

antimicrobial therapy; Bioavailability; Fluoroquinolones; ICUs; Pneumonia; Probability of target attainment

Indexed keywords

CREATININE; MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG SCREENING; DRUG WITHDRAWAL; ENTERAL DRUG ADMINISTRATION; ENTERIC FEEDING; ENTEROBACTER CLOACAE; FEMALE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HAFNIA ALVEI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NOSE FEEDING; OPEN STUDY; PATHOGENESIS; PLASMA CONCENTRATION-TIME CURVE; PROTEUS MIRABILIS; QT PROLONGATION; RISK ASSESSMENT; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SERRATIA MARCESCENS; SIDE EFFECT; STEADY STATE; TREATMENT DURATION; ADOLESCENT; ALGORITHM; APACHE; AREA UNDER THE CURVE; BIOAVAILABILITY; COHORT ANALYSIS; COMPUTER SIMULATION; CRITICAL ILLNESS; FLUOROMETRY; MIDDLE AGED; POPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; APACHE; AREA UNDER CURVE; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; COMPUTER SIMULATION; CRITICAL ILLNESS; ENTERAL NUTRITION; FEMALE; FLUOROMETRY; FLUOROQUINOLONES; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; POPULATION; QUINOLINES; RESPIRATION, ARTIFICIAL; YOUNG ADULT;

EID: 84891434584     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt040     Document Type: Article

References (29)

1. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005; 118: 29-38.
2. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-6.
3. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R D 2012; 12: 71-100.
4. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
5. Albertson TE, Dean NC, El Solh AA et al. Fluoroquinolones in the management of community-acquired pneumonia. Int J Clin Pract 2010; 64: 378-88.
6. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59: 115-39.
7. Welte T, Petermann W, Schürmann D et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697-705.
8. Buyle F, Vogelaers D, Peleman R et al. Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospital. Pharm World Sci 2010; 32: 404-10.
9. Varghese JM, Roberts JA, Lipman J. Pharmacokinetics and pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol 2010; 23: 472-8.
10. Udy AA, Roberts JA, De Waele JJ et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39: 455-7.
11. Pletz MW, Bloos F, Burkhardt O et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med 2010; 36: 979-83.
12. Leone M, Albanèse J, Sampol-Manos E et al. Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother 2004; 48: 638-40.
13. Stass H, Rink AD, Delesen H et al. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58: 693-6.
14. De Smet J, Colpaert K, De Paepe P et al. Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study. Scand J Infect Dis 2012; 1-5.
15. Kees MG, Weber S, Kees F et al. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother 2011; 66: 2330-5.
16. Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res 1998; 15: 1463-8.
17. Ambrose PG, Bhavnani SM, Rubino CM et al. Antimicrobial resistance: pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
18. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43: 83-90.
19. Stass H, Kubitza D, Halabi A et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002; 53: 232-7.
20. Burkhardt O, Stass H, Thuss U et al. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet 2005; 44: 969-76.
21. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998; 27: 33-9.
22. Roberts JA, Kruger P, Paterson DL et al. Antibiotic resistance-what's dosing got to do with it? Crit Care Med 2008; 36: 2433-40.
23. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96
24. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-48.
25. Rolston KV, Frisbee-Hume S, LeBlanc B et al. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis 2003; 47: 441-9.
26. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003; 37: 1478-88.
27. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ et al. Pharmacokineticpharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 2010; 51 Suppl 1: S103-10.
28. Hö ffken G, Barth J, Rubinstein E et al. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia. Infection 2007;35:414-20
29. Ott S, Allewelt M, Lorenz J et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36: 23-30.